Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in San Diego, CA
NPI: 1144431230Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get M.D. Ayad's Phone Numberphone_androidMobile
Get M.D. Ayad's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2019 - 2027
MA State Medical License
2008 - 2020
OH State Medical License
2005 - 2008
American Board of Internal Medicine
Hematology
Beth Israel Deaconess Medical Center
Fellowship • Hematology and Medical Oncology
2008 - 2011
Case Western Reserve University/University Hospitals Cleveland Medical Center
Residency • Internal Medicine
2005 - 2008
American University of Beirut Faculty of Medicine
Medical School
Until 2003
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 95 | 253 |
| 2 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 57 | 292 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 33 | 33 |
| 4 | 99239Hospital discharge day management, more than 30 minutes | 21 | 23 |
| 5 | 99223Initial hospital inpatient care, typically 70 minutes per day | 11 | 11 |
Authors: Jeremy Abramson, Daniel Kuritzkes, Francisco Marty
Journal: PLoS One
Publication Date: 2018-05-10
Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia.
Authors: Erik Uhlmann, Robin Marie Joyce, Dimitrios Tzachanis
Publication Date: 2014-01
Photoluminescence spectra of CdSe/ZnS quantum dots in solution.
Authors: Ibnaouf, K H, Prasad, Saradh, Hamdan, A, Alsalhi, M, Aldwayyan, A S, Zaman, M B, Masilamani, V
Journal: Spectrochim Acta A Mol Biomol Spectrosc
Publication Date: 2013-11-01
Lead Sponsor: Washington University School of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Intervention / Treatment: BIOLOGICAL: rituximab
Lead Sponsor: Artiva Biotherapeutics, Inc.
Intervention / Treatment: DRUG: Rituximab, DRUG: Bendamustine, DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: Interleukin-2, DRUG: AB-101
Lead Sponsor: Karyopharm Therapeutics Inc
Intervention / Treatment: DRUG: Venetoclax, DRUG: Rituximab, DRUG: Lenalidomide, DRUG: Bendamustine, DRUG: Selinexor, DRUG: Ibrutinib, DRUG: Gemcitabine, DRUG: Oxaliplatin, DRUG: Tafasitamab, DRUG: Polatuzumab Vedotin